Dendritic Cell Vaccines for Cancer Therapy: Fundamentals and Clinical TrialsBreast cancerColorectal cancerDC vaccineDendritic cellsCancer immunotherapyMelanomaProstate cancerOne of the main challenges in antitumor immunotherapy is the low immunogenicity of tumor cells and the tolerogenic tumor microenvironment. ...
their limited success in larger clinical trials highlights the need to optimize DC vaccine preparations. This chapter describes the methodologies utilized
Karolina Palucka is a scientific founder of ODC Therapy, Inc., and she also has stock options. These private companies undertake research associated with dendritic-cell vaccines. Neither one of them has in any way supported the clinical trials, the results of which are described in this paper....
Dendritic Cell Vaccines have been around for over 20 years but early results suggested they had an effect in only 12% of brain cancer patients; but now in a new 4 country clinical trial, Dendritic Cell Vaccine (DCVax-L) seems to give some patients over 7 years of extra survival, fulfillin...
Keywords : Dendritic cell, Vaccines, Breast cancer, Immune regulation, Immunotherapy Plan Introduction DCs and DC-based vaccines Biology of DCs Preparation and types of DC-based vaccines DC-based vaccines in immunomodulation of BC DC polypeptide vaccine DC gene vaccines Clinical application of DC-based...
Dendritic cell (DC) vaccines represent a personalized approach in cancer immunotherapy, utilizing the patient's own dendritic cells to stimulate an immune response against cancer cells. The paper overviews the mechanisms of DC vaccines and their clinical applications in acute myeloid leukemia (AML), ...
More specifically the present invention discloses describes an autologous dendritic cell (DC) vaccine product derived by culturing a patient's monocytes with granulocyte macrophage colony stimulating factor (GM-CSF) and interferon alpha 2b (IFN-α), loading the DC with a mixture of five lipopeptides...
Fast track status has been granted by the FDA to the dendritic cell vaccine (DCV) DOC1021 for pancreatic ductal adenocarcinoma (PDAC), according to a news release from the developer, Diakonos Oncology.1 Support for the fast track status follows phase 1 results demonstrating prolonged ove...
Locke and colleagues designed adendritic cell vaccinetargeting a protein called survivin and tested this vaccine in a phase I clinical trial involving 13 patients with multiple myeloma. Patients received one dose of the vaccine within 30 days before standard-of-care ASCT and another dose approximately...
Modest clinical outcomes of dendritic-cell (DC) vaccine trials call for the refinement of DC vaccine design. Although many potential antigens have been ide... BA Hanks,J Jiang,RA Singh,... - 《Nature Medicine》 被引量: 200发表: 2005年 Enhancement of the priming efficacy of DNA vaccines ...